The following correction has been made to this paper [1]: We would like to inform the readers that our colleague, Jirina Martinkova, asked to be excluded as an author in this communication. Although we regret her decision, we have respectfully fulfilled her request and wish her the best in her future endeavors. All authors accepted this change and signed Change of Authorship Form.
Author Contributions
S.F. and O.K. wrote the article (S.F.–corresponding author), J.Š. consulting of clinical experiences, M.B. and M.L. consulting of plasmafiltration method. All authors have read and agreed to the published version of the manuscript.
Funding
This review was supported by the Ministry of Health CZ, grant number AZV 16-30366A and PROGRES Q40/06.
Conflicts of Interest
The authors declare no conflict of interest.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Reference
- 1.Filip S., Kubeček O., Špaček J., Lánská M., Bláha M. Therapeutic apheresis, circulating PLD, and mucocutaneous toxicity: our clinical experience through four years. Pharmaceutics. 2020;12:940. doi: 10.3390/pharmaceutics12100940. [DOI] [PMC free article] [PubMed] [Google Scholar]